Clinical Trial Update: Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer [Phase 2]

View source ↗

Summary

Phase II study of Lutetium-177 labeled girentuximab for metastatic clear cell renal cell carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma

Drugs mentioned

• Lutetium-177 labeled girentuximab (girentuximab (177Lu-labeled))

Snippet

Sponsor: Radboud University Medical Center | Conditions: Metastatic Clear Cell Renal Cell Carcinoma | Phase 2 | Status: COMPLETED